Anti-NTPDase1/CD39 antibodies facilitate intra-tumor T cell infiltration overcoming resistance to PD-1 blockade, therefore showing potentially useful activity in the adoptive T-cell transfer therapy (Li et al., 2019). Here, ENTPD1 is linked to neoplasm.